Sarcoma & GIST
From the Journals
Oncologists Voice Ethical Concerns Over AI in Cancer Care
Researchers ask 204 oncologists from 37 states for their views on the ethical implications of using AI for cancer care.
Conference Coverage
Circulating Tumor DNA Predicts Early Treatment Response in Patients With HER2-Positive Cancers
New study results suggest ctDNA dynamics provide an early window into predicting response to targeted therapies in patients with HER2-altered...
Conference Coverage
Repeat MCED Testing May ID Early-Stage and Unscreened Cancers
Eight of 26 patients with cancer signals detected through MCED had cancer.
From the Journals
Less Than 50% of Accelerated Approvals Show Clinical Benefit
Researchers review 46 cancer drugs granted accelerated approvals between 2013 and 2017.
From the Journals
Virtual Reality Brings Relief to Hospitalized Patients With Cancer
Patients were randomized to receive either 10 minutes of immersive VR distraction therapy or 10 minutes of two-dimensional guided imagery...
Feature
Should Opioids Be Used for Chronic Cancer Pain?
Prescribing strategies are partly driven by peer pressure, new research suggests.
Commentary
A Banned Chemical That Is Still Causing Cancer
This carcinogen ‘is still around: in our soil, in our food, and in our blood.’
From the Journals
Active Surveillance for Cancer Doesn’t Increase Malpractice Risk
Researchers identify malpractice trends involving active surveillance related to thyroid, prostate, kidney, and...
From the Journals
Few Childhood Cancer Survivors Get Recommended Screenings
‘As many as four out of five of these survivors will develop a serious or life-threatening late effect of their cancer therapy by age 45,’ the...
From the Journals
Most Cancer Trial Centers Located Closer to White, Affluent Populations
Researchers compare the distributions of patients of different races and socioeconomic statuses to the locations of clinical research facilities...
Commentary
New Drug Approvals Are the Wrong Metric for Cancer Policy
How should we define success in cancer policy — what should the endpoint be?